

97904948.3 PCT/BE97/00023

(9)



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

REC'D 07 APR 1997

WIPO PCT

Bescheinigung

Certificate

Attestation

Die angehefteten Unterla-  
gen stimmen mit der  
ursprünglich eingereichten  
Fassung der auf dem näch-  
sten Blatt bezeichneten  
europäischen Patentanmel-  
dung überein.

The attached documents  
are exact copies of the  
European patent application  
described on the following  
page, as originally filed.

Les documents fixés à  
cette attestation sont  
conformes à la version  
initialement déposée de  
la demande de brevet  
européen spécifiée à la  
page suivante.

Patentanmeldung Nr. Patent application No. Demande de brevet n°

96870102.9

PRIORITY DOCUMENT

Der Präsident des Europäischen Patentamts:  
Im Auftrag

For the President of the European Patent Office

Le Président de l'Office européen des brevets  
p.o.

DEN HAAG  
THE HAGUE  
LA HAYE

21/03/97

EPA/EPO/OEB 1014 - 02.91

Applicants: Graham P. Allaway et al.  
Serial No.: 09/888,938  
Filed: June 25, 2001  
Exhibit 8

BEST AVAILABLE COPY



Europäisches  
Patentamt

European  
Patent Office

Office européen  
des brevets

**Blatt 2 der Bescheinigung**  
**Sheet 2 of the certificate**  
**Page 2 de l'attestation**

Anmeldung Nr.  
Application no.  
Demande n° 96870102.9

Anmeldetag  
Date of filing  
Date de dépôt 06/08/96

Anmelder  
Applicant(s)  
Demandeur(s)  
EUROSCREEN S.A.  
1160 Bruxelles  
BELGIUM

Bezeichnung der Erfindung  
Title of the invention  
Titre de l'invention

Active and inactive CC-chemokines receptor and nucleic acid molecules encoding said receptor

In Anspruch genommene Priorat(en) / Priority(ies) claimed / Priorité(s) revendiquée(s)

Staat  
State  
Pays

Tag  
Date  
Date

Aktenzeichen  
File no.  
Numéro de dépôt

Internationale Patentklassifikation  
International Patent classification  
Classification internationale des brevets

C07K14/00

Am Anmeldetag benannte Vertragsstaaten  
Contracting states designated at date of filing: AT/BE/CH/DE/DK/ES/FI/FR/GB/GR/IE/IT/LI/LU/MC/NL/PT/SE  
Etats contractants désignés lors du dépôt

Bemerkungen  
Remarks  
Remarques

5

ACTIVE AND INACTIVE CC-CHEMOKINES RECEPTOR AND NUCLEIC  
ACID MOLECULES ENCODING SAID RECEPTOR.

10 Field of the present invention.

The present invention concerns new peptides and the nucleic acid molecules encoding said peptides, the vector comprising said nucleic acid molecules, the cells transformed by said vector, inhibitors directed against said peptides or  
15 said nucleic acid molecules, a pharmaceutical composition and a diagnostic and/or dosage device comprising said products, and non human transgenic animals expressing the peptides according to the invention or the nucleic acid molecules encoding said peptides.

20 The invention further provides a method for determining ligand binding, detecting expression, screening for drugs binding specifically to said peptides and treatments involving the peptides or the nucleic acid molecules according to the invention.

25

Technological background and state of the art.

Chemotactic cytokines, or chemokines, are small signalling proteins that can be divided in two subfamilies (CC- and CXC-chemokines) depending on the relative position  
30 of the first two conserved cysteines. Interleukin 8 (IL-8) is the most studied of these proteins, but a large number of chemokines (Regulated on Activation Normal T-cell Expressed

and Secreted (RANTES), Monocyte Chemoattractant Protein 1 (MCP-1), Monocyte Chemoattractant Protein 2 (MCP-2), Monocyte Chemoattractant Protein 3 (MCP-3), Growth-Related gene product  $\alpha$  (GRO $\alpha$ ), Growth-Related gene product  $\beta$  (GRO $\beta$ ),  
 5 Growth-Related gene product  $\gamma$  (GRO $\gamma$ ), Macrophage Inflammatory Protein 1 $\alpha$  (MIP-1 $\alpha$ ) and  $\beta$ , etc.) has now been described [4]. Chemokines play fundamental roles in the physiology of acute and chronic inflammatory processes as well as in the pathological dysregulations of these processes, by attracting  
 10 and simulating specific subsets of leucocytes [32]. RANTES for example is a chemoattractant for monocytes, memory T-cells and eosinophils, and induces the release of histamine by basophils. MCP-1, released by smooth muscle cells in arteriosclerotic lesions, is considered as the factor (or one  
 15 of the factors) responsible for macrophage attraction and, therefore, for the progressive aggravation of the lesions [4].

MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES chemokines have recently been described as major HIV-suppressive factors produced by  
 20 CD8<sup>+</sup> T-cells [9]. CC-chemokines are also involved in the regulation of human myeloid progenitor cell proliferation [6, 7].

Recent studies have demonstrated that the actions of CC- and CXC-chemokines are mediated by subfamilies of G  
 25 protein-coupled receptors. To date, despite the numerous functions attributed to chemokines and the increasing number of biologically active ligands, only six functional receptors have been identified in human. Two receptors for interleukin-8 (IL-8) have been described [20, 29]. One (IL-8RA) binds IL-  
 30 8 specifically, while the other (IL-8RB) binds IL-8 and other CXC-chemokines, like GRO. Among receptors binding CC-chemokines, a receptor, designated CC-chemokine receptor 1

(CC-CKR1), binds both RANTES and MIP-1 $\alpha$  [31], and the CC-chemokine receptor 2 (CC-CKR2) binds MCP-1 and MCP-3 [8, 44, 15]. Two additional CC-chemokine receptors were cloned recently : the CC-chemokine receptor 3 (CC-CKR3) was found  
5 to be activated by RANTES, MIP-1 $\alpha$  and MIP-1 $\beta$  [10]; the CC-chemokine receptor 4 (CC-CKR4) responds to MIP-1, RANTES and MCP-1 [37]. In addition to these six functional receptors, a number of orphan receptors have been cloned from human and other species, that are structurally related to either CC-  
10 or CXC-chemokine receptors. These include the human BLR1 [13], EBI1 [5], LCR1 [21], the mouse MIP-1 RL1 and MIP-1 RL2 [17] and the bovine PPR1 [25]. Their respective ligand(s) and function(s) are unknown at present.

15 Summary of the invention.

The present invention is related to a peptide having at least an amino sequence which presents more than 80%, advantageously more than 90%, preferably more than 95%, homology with the amino sequence as represented in SEQ ID  
20 NO. 1.

Preferably, said peptide has also at least an amino sequence which presents more than 80%, advantageously more than 90%, preferably more than 95%, homology with the amino sequence as represented in SEQ ID NO. 2.

25 According to another embodiment of the present invention, the peptide has at least an amino sequence which presents more than 80%, advantageously more than 90%, preferably more than 95%, homology with the amino sequence as represented in SEQ ID NO. 3.

30 Therefore, according to the invention, the amino sequence as represented in SEQ ID NO. 1 is the common amino acid sequence of SEQ ID NO. 2 and of SEQ ID NO. 3 (see also

figure 1). Therefore, a first industrial application of said amino sequence is the identification of the homology between said amino acid sequence and the screening of various mutants encoding a different amino acid sequence than the one previously described, and the identification of various types of patient which may present a predisposition or a resistance to the disorders described in the following specification.

Preferably, said peptide is an active CC-chemokine receptor or a portion thereof.

10 A "portion of an amino acid sequence" means a peptide or a protein having the same binding properties as the whole receptor according to the invention. Said portion could be an epitope which is specifically binded by a ligand of said receptor which could be the "natural ligand", an agonist or an analog of said ligand, or an inhibitor of said  
15 ligand to said receptor (including the antagonists of said ligand).

Advantageously, the CC-chemokine receptor according to the invention is stimulated by the MIP-1 $\beta$  chemokine at a concentration less or equal to 10 nm, and is advantageously  
20 also stimulated by the MIP-1 $\alpha$  or RANTES chemokines. However, said chemokine receptor is not stimulated by the MCP-1, MCP-2, MCP-3, IL-8 and GRO $\alpha$  chemokines.

In addition, the peptide is also a receptor of HIV  
25 viruses or a portion of said HIV viruses.

It is meant by "HIV viruses" HIV-1 or HIV-2 and all the various strains of HIV viruses which are involved in the development of AIDS. It is meant by a "portion of HIV viruses" any part of said viruses which is able to interact  
30 with said receptor. Among said portions of viruses which may be involved in the interaction with the peptide according to the invention, are proteins encoded by the ENV and GAG

viruses genes.

Preferably, said portion of HIV viruses is the glycoprotein gp120/160 (membrane-bound gp160 or the free gp derived therefrom) or a portion thereof.

5 It is meant by a "portion of the glycoprotein gp120/160" any epitope, preferably an immuno-dominant epitope, of said glycoprotein which may interact specifically with the peptide according to the invention, such as for instance the V3 loop (third hypervariable domain).

10 According to another embodiment of the present invention, the peptide according to the invention is an inactive CC-chemokine receptor. An example of such inactive CC-chemokine receptor is encoded by the amino acid sequence as represented in SEQ ID NO. 2.

15 It is meant by an "inactive CC-chemokine receptor" a receptor which is not stimulated by any known CC-chemokine, especially the MIP-1 $\beta$ , MIP-1 $\alpha$  or RANTES chemokines.

The peptide according to the invention may also be an inactive receptor which is not a receptor of HIV viruses  
20 or of a portion of said HIV viruses, which means that said inactive receptor does not allow the entry of said HIV into the cell having said receptor.

Said peptide could be a human receptor or a human inactive receptor.

25 The present invention concerns also the nucleic acid molecule having more than 80%, preferably more than 90%, homology with one of the nucleic acid sequences shown in the figures 1.

Preferably, said nucleic acid molecule has at least  
30 the nucleic acid sequence shown in said figure or a portion thereof.

It is meant by a "portion of said nucleic acid molecule" any specific nucleic acid sequence of more than 15 nucleotides which could be used in order to detect and/or reconstitute said nucleic acid molecule or its complementary strand. Such portion could be a probe or a primer which could be used in genetic amplification using the PCR, LCR or CPR techniques for instance.

The present invention concerns more specifically the nucleic acid molecules encoding the peptide according to the invention. Said nucleic acid molecules are RNA or DNA molecules such as a cDNA molecule or a genomic DNA molecule.

The present invention is also related to a vector comprising the nucleic acid molecule according to the invention. Preferably, said vector is adapted for expression in a cell and comprises the regulatory elements necessary for expressing the amino acid molecule in said cell operatively linked to the nucleic acid sequence according to the invention as to permit expression thereof.

Preferably, said cell is chosen among the group consisting of bacterial cells, yeast cells, insect cells or mammalian cells. The vector according to the invention is a plasmid, preferably a pcDNA3 plasmid, or a virus, preferably a baculovirus, an adenovirus or a semliki forest virus.

The present invention concerns also the cell, preferably a mammalian cell, such as a CHO-K1 or a HEK293 cell, transformed by the vector according to the invention. Advantageously, said cell is non neuronal in origin and is chosen among the group consisting of CHO-K1, HEK293, BHK21, COS-7 cells.

The present invention also concerns the cell (preferably a mammalian cell such as a CHO-K1 cell) transformed by the vector according to the invention and by



another vector encoding a protein enhancing the functional response in said cell. Advantageously, said protein is the G $\alpha$ 15 or G $\alpha$ 16 (G protein,  $\alpha$  subunit).

The present invention is also related to a nucleic acid probe comprising a nucleic acid molecule of at least 15 nucleotides capable of specifically hybridizing with a unique sequence included within the sequence of the nucleic acid molecule according to the invention. Said nucleic acid probe may be a DNA or a RNA.

10 The invention concerns also an antisense oligonucleotide having a sequence capable of specifically hybridizing to an mRNA molecule encoding the peptide according to the invention so as to prevent translation of said mRNA molecule or an antisense oligonucleotide having a  
15 sequence capable of specifically hybridizing to the cDNA molecule encoding the peptide according to the invention.

Said antisense oligonucleotide may comprise chemical analogs of nucleotide or substances which inactivate mRNA, or be included in an RNA molecule endowed with ribozyme  
20 activity.

Another aspect of the present invention concerns a ligand (preferably an antibody) other than known natural ligands, chosen among the group consisting of known chemokines, HIV viruses or a portion of said HIV viruses;  
25 said ligand being capable of binding to a peptide according to the invention and capable of competitively inhibiting the binding of the natural known ligand to the peptide according to the invention. The exclusion in the above identified definition of known chemokines, HIV viruses or a portion of  
30 said HIV viruses, does not include variants of said "natural" viruses or said "natural" portion which may be obtained for instance by genetic engineering and which may mimic the

interaction of said viruses and portion of said viruses to the peptide according to the invention and are thus capable of binding to a peptide according to the invention and capable of competitively inhibiting the binding of said  
5 natural ligand to the peptide according to the invention.

Preferably, said antibody is a monoclonal antibody.

The present invention concerns also the monoclonal antibody directed to an epitope of the peptide according to the invention and present on the surface of a cell expressing  
10 said peptide.

The invention concerns also the pharmaceutical composition comprising either an effective amount of the peptide according to the invention (in order to delude the HIV virus from the natural peptide present at the surface of  
15 a mammalian cell and stop the infection of said mammalian cell by the HIV virus), or an effective amount of the above identified described ligand, or an effective amount of oligonucleotide according to the invention, effective to decrease the activity of said peptide by passing through a  
20 cell membrane and binding specifically with mRNA encoding the peptide according to the invention in the cell so as to prevent its translation. The pharmaceutical composition comprises also a pharmaceutically acceptable carrier capable of passing through said cell membrane.

25 Preferably, in said pharmaceutical composition, the oligonucleotide is coupled to a substance, such as a ribozyme, which inactivates mRNA.

Preferably, the pharmaceutically acceptable carrier comprises a structure which binds to a receptor on a cell  
30 capable of being taken up by cell after binding to the structure. The structure of the pharmaceutically acceptable carrier in said pharmaceutical composition is capable of

binding to a receptor which is specific for a selected cell type.

Preferably, said pharmaceutical composition comprises an amount of the antibody according to the invention effective to block the binding of a ligand to the peptide according to the invention and a pharmaceutically acceptable carrier.

The present invention concerns also a transgenic non human mammal overexpressing (or expressing ectopically) the nucleic acid molecule encoding the peptide according to the invention.

The present invention also concerns a transgenic non human mammal comprising an homologous recombination knockout of the native peptide according to the invention.

According to a preferred embodiment of the invention, the transgenic non human mammal whose genome comprises antisense nucleic acid complementary to the nucleic acid according to the invention is so placed as to be transcribed into antisense mRNA which is complementary to the mRNA encoding the peptide according to the invention and which hybridizes to mRNA encoding said peptide, thereby reducing its translation. Preferably, the transgenic non human mammal according to the invention comprises a nucleic acid molecule encoding the peptide according to the invention and comprises additionally an inducible promoter or a tissue specific regulatory element.

Preferably, the transgenic non human mammal is a mouse.

The invention relates to a method for determining whether a ligand can be specifically bound to the peptide according to the invention, which comprises contacting a cell transfected with a vector expressing the nucleic acid

molecule encoding said peptide with the ligand under conditions permitting binding of ligand to such peptide and detecting the presence of any such ligand bound specifically to said peptide, thereby determining whether the ligand binds specifically to said peptide.

The invention relates to a method for determining whether a ligand can specifically bind to a peptide according to the invention, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the ligand with the membrane fraction under conditions permitting binding of the ligand to such peptide and detecting the presence of any ligand bound to said peptide, thereby determining whether the compound is capable of specifically binding to said peptide. Preferably, said method is used when the ligand is not previously known.

The invention relates to a method for determining whether a ligand is an agonist of the peptide according to the invention, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide with the ligand under conditions permitting the activation of a functional peptide response from the cell and detecting by means of a bio-assay, such as a modification in a second messenger concentration (preferably calcium ions or inositol phosphates such as  $IP_3$ ) or a modification in the cellular metabolism (preferably determined by the acidification rate of the culture medium), an increase in the peptide activity, thereby determining whether the ligand is a peptide agonist.

The invention relates to a method for determining whether a ligand is an agonist of the peptide according to

the invention, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the membrane fraction with the ligand under conditions permitting the activation of a functional peptide response and detecting by means of a bio-assay, such as a modification in the production of a second messenger (preferably inositol phosphates such as  $IP_3$ ), an increase in the peptide activity, thereby determining whether the ligand is a peptide agonist.

The present invention relates to a method for determining whether a ligand is an antagonist of the peptide according to the invention, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide with the ligand in the presence of a known peptide agonist, under conditions permitting the activation of a functional peptide response and detecting by means of a bio-assay, such as a modification in second messenger concentration (preferably calcium ions or inositol phosphates such as  $IP_3$ ) or a modification in the cellular metabolism (preferably determined by the acidification rate of the culture medium), a decrease in the peptide activity, thereby determining whether the ligand is a peptide antagonist.

The present invention relates to a method for determining whether a ligand is an antagonist of the peptide according to the invention, which comprises preparing a cell extract from cells transfected with an expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cells extract, contacting the membrane fraction with the ligand in the presence of a known peptide agonist, under conditions permitting the activation of a

functional peptide response and detecting by means of a bio-assay, such as a modification in the production of a second messenger, a decrease in the peptide activity, thereby determining whether the ligand is a peptide antagonist.

5            Preferably, the second messenger assay comprises measurement of calcium ions or inositol phosphates such as  $IP_3$ .

            Preferably, the cell used in said method is a mammalian cell non neuronal in origin, such as CHO-K1,  
10 HEK293, BHK21, COS-7 cells.

            The present invention also concerns the cell (preferably a mammalian cell such as a CHO-K1 cell) transformed by the vector according to the invention and by another vector encoding a protein enhancing the functional  
15 response in said cell. Advantageously, said protein is the G $\alpha$ 15 or G $\alpha$ 16 (G protein,  $\alpha$  subunit).

            In said method, the ligand is not previously known.

            The invention is also related to the ligand isolated and detected by any of the preceding methods.

20            The present invention concerns also the pharmaceutical composition which comprises an effective amount of an agonist or an antagonist of the peptide according to the invention, effective to reduce the activity of said peptide and a pharmaceutically acceptable carrier.

25            It is meant by "an agonist or an antagonist of the peptide according to the invention", all the agonists or antagonists of the natural ligand of said peptide as above described.

            Therefore, the previously described methods may be  
30 used for the screening of drugs to identify drugs which specifically bind to the peptide according to the invention.

The invention is also related to the drugs isolated and detected by any of these methods.

The present invention concerns also a pharmaceutical composition comprising said drugs and a  
5 pharmaceutically acceptable carrier.

The invention is also related to a method of detecting expression of a peptide according to the invention by detecting the presence of mRNA coding for a peptide, which comprises obtaining total RNA or total mRNA from the cell and  
10 contacting the RNA or mRNA so obtained with the nucleic acid probe according to the invention under hybridizing conditions and detecting the presence of mRNA hybridized to the probe, thereby detecting the expression of the peptide by the cell.

Said hybridization conditions are stringent  
15 conditions.

The present invention concerns also the use of the pharmaceutical composition according to the invention for the treatment and/or prevention of inflammatory diseases, including rheumatoid arthritis, glomerulonephritis, asthma,  
20 idiopathic pulmonary fibrosis and psoriasis, viral infections including Human Immunodeficiency Viruses 1 and 2 (HIV-1 and 2), cancer including leukaemia, atherosclerosis and/or auto-immune disorders.

The present invention concerns also a method for  
25 diagnosing a predisposition or a resistance to a disorder associated with the activity of the peptide according to the invention and/or associated with infectious agents such as HIV viruses in a subject. Said method comprises :

- a) obtaining nucleic acid molecules of a subject;
- 30 b) possibly performing a restriction digest of said nucleic acid molecules with a panel of restriction enzymes;
- c) possibly electrophoretically separating the resulting

nucleic acid fragments on a sized gel;

- d) contacting the resulting gel or the obtained nucleic acid molecule with a nucleic acid probe labelled with a detectable marker and capable of specifically hybridizing to said nucleic acid molecule (said hybridization being made in strengent hybridization conditions);
- e) detecting labelled bands or the in situ nucleic acid molecules which have hybridized to the said nucleic acid molecule labelled with a detectable marker to create a unique band pattern or an in situ marking specific to the subject;
- f) preparing other nucleic acid molecules obtained from other patients for diagnosis by step a-e; and
- g) comparing the unique band pattern specific to the nucleic acid molecule of subjects suffering from the disorder from step e and the nucleic acid molecule obtained for diagnosis from step f to determine whether the patterns are the same or different and to diagnose thereby a predisposition or a resistance to the disorder if the patterns are the same or different.

The present invention is also related to a method for diagnosing a predisposition or a resistance to a disorder associated with the activity of a specific allele of the peptide according to the invention or the presence of said peptide at the surface of cells and/or associated with infectious agents such as HIV viruses present in a subject. Said method comprises :

- a) obtaining a sample of a body fluid, preferably a blood sample comprising antigen presenting cells, from a subject;
- b) adding to said sample a ligand and/or an anti-ligand



according to the invention;

- c) detecting the cross-reaction between said ligand and/or said anti-ligand and the specific peptide according to the invention; and
- 5 d) determining whether the peptide corresponds to a receptor or an inactive receptor according to the invention and diagnosing thereby a predisposition or a resistance to the disorder according to the type of the peptide present in the body fluid of the subject.

10 The present invention concerns also diagnostic and/or dosage devices comprising the peptides, the nucleic acid molecules, the nucleic acid probes, the ligands and/or the anti-ligands according to the invention, being possibly labelled with a detectable marker, their portions (such as  
15 primers, probes, epitopes, ...) or a mixture thereof.

Said diagnostic and/or dosage devices comprise also the reactants for the detection and/or the dosage of antigens, antibodies or nucleic acid sequences through a method selected from the group consisting of in situ  
20 hybridization, hybridization or recognition by marked specific antibodies, specially ELISA ® (Enzyme Linked Immunosorbent Assay) or RIA ® (Radio Immunoassay), methods on filter, on a solid support, in solution, in "sandwich", on gel, by Dot blot hybridization, by Northern blot  
25 hybridization, by Southern blot hybridization, by isotopic or non-isotopic labelling (such as immunofluorescence or biotinylation), by a technique of cold probes, by genetic amplification, particularly PCR, LCR or CPR, by a double immunodiffusion, by a counter-immunoelectrophoresis, by  
30 haemagglutination and/or a mixture thereof.

A last aspect of the present invention concerns a

method of preparing the purified peptide according to the invention, which comprises :

- a) constructing a vector adapted for expression in a cell which comprises the regulatory elements necessary for the expression of nucleic acid molecules in the cell operatively linked to nucleic acid molecule encoding said peptide so as to permit expression thereof, wherein the cell is selected from the group consisting of bacterial cells, yeast cells, insect cells and mammalian cells;
- b) inserting the vector of step a in a suitable host cell;
- c) incubating the cell of step b under conditions allowing the expression of the peptide according to the invention;
- d) recovering the peptide so obtained; and
- e) purifying the peptide so recovered, thereby preparing an isolated peptide according to the invention.

Short description of the drawings.

The figure 1 represents the primary structure of the peptides according to the invention.

- The figure 2 represents the amino acids sequence of the active human CCR5 chemokine receptor according to the invention aligned with that of the human CCR1, CCR2B, CCR3 and CCR4 receptors. Amino acids identical with the active CCR5 sequence are boxed.

The figure 3 shows the chromosomal organisation of the human CCR2 and CCR5 chemokine receptor genes.

The figure 4 shows the functional expression of the human active CCR5 receptor in a CHO-K1 cell line.

The figure 5 represents the distribution of mRNA encoding the CCR5 receptor in a panel of human cell

lines of haematopoietic origin.

The figure 6 represents the structure of the mutant form of human CCR5 receptor.

5 The figure 7 represents the quantification of ENV proteins-mediated fusion by luciferase assays.

The figure 8 represents genotyping of individuals by PCR and segregation of the CCR5 alleles in CEPH families.

10 Detailed description of the invention.

1. EXPERIMENTALS

Materials

Recombinant human chemokines, including MCP-1, MIP-1 $\alpha$ , MIP-1 $\beta$ , RANTES, IL-8 and GRO $\alpha$  were obtained from R & D Systems (London, UK). MCP-2 and MCP-3 were a gift of J. Van Damme, University of Leuven, Belgium. [<sup>125</sup>I]MIP-1 $\alpha$  (specific activity, 2200 Ci/mmol) was obtained from Dupont NEN (Brussels, Belgium). Chemokines obtained from R & D Systems were reported by the supplier as >97 % pure on SDS-PAGE  
15 (sodium dodecyl sulphate-polyacrylamide gel electrophoresis) and biologically active on a bioassay specific for each ligand. The lyophilized chemokines were dissolved as a 100  $\mu$ g/ml solution in a sterile phosphate-buffered saline (PBS) and this stock solution was stored at -20° C in  
20 aliquots. Chemokines were diluted to the working concentration immediately before use. All cell lines used in the present study were obtained from the ATCC (Rockville, MD, USA).

30

Cloning and sequencing

The mouse MOP020 clone was obtained by low

stringency polymerase chain reaction, as described previously [24, 34], using genomic DNA as template. A human genomic DNA library (Stratagene, La Jolla, CA) constructed in the lambda DASH vector was screened at low stringency [39] with the MOP020 (511 bp) probe. The positive clones were purified to homogeneity and analysed by Southern blotting. The restriction map of the locus was determined and a relevant XbaI fragment of 4,400 bp was subcloned in pBluescript SK+ (Stratagene). Sequencing was performed on both strands after subcloning in M13mp derivatives, using fluorescent primers and an automated DNA sequencer (Applied Biosystem 370A). Sequence handling and data analysis was carried out using the DNASIS/PROSIS software (Hitachi), and the GCG software package (Genetics Computer Group, Wisconsin).

15

#### Expression in cell lines

The entire coding region was amplified by PCR as a 1056 bp fragment, using primers including respectively the BamHI and XbaI recognition sequences, and cloned after restriction in the corresponding sites of the eukaryotic expression vector pcDNA3 (Invitrogen, San Diego, CA). The resulting construct was verified by sequencing, and transfected in CHO-K1 cells as described [35]. Two days after transfection, selection for stably transfected cell lines was initiated by the addition of 400 µg/ml G418 (Gibco), and resistant clones were isolated at day 10. CHO-K1 cells were cultured using Ham's F12 medium, as previously described [35, 11]. The expression of the active CCR5 receptor in the various cell clones was evaluated by measuring the specific transcript level by Northern blotting, on total RNA prepared from the cells (see below).

30

### Binding Assays

Stably transfected CHO-K1 cells expressing the active CCR5 receptor were grown to confluence and detached from culture dishes by incubation in phosphate-buffered saline (PBS) supplemented with 1 mM EDTA. Cells were collected by low speed centrifugation and counted in a Neubauer cell. Binding assays were performed in polyethylene minisorp tubes (Nunc) in a final volume of 200  $\mu$ l PBS containing 0.2 % bovine serum albumin (BSA) and  $10^6$  cells, in presence of [ $^{125}$ I]-MIP-1 $\alpha$ . Non specific binding was determined by addition of 10 nM unlabelled MIP-1 $\alpha$ . The concentration of labelled ligand was 0.4 nM (around 100 000 cpm per tube). The incubation was carried out for 2 hours at 4 °C, and was stopped by the rapid addition of 4 ml ice-cold buffer, and immediate collection of cells by vacuum filtration through GF/B glass fiber filters (Whatmann) pre-soaked in 0.5 % polyethylenimine (Sigma). Filters were washed three times with 4 ml ice-cold buffer and counted in a gamma counter.

### 20 Biological activity

The CHO-K1 cell lines stably transfected with the pcDNA3/CCR5 construct or wild type CHO-K1 cells (used as controls) were plated onto the membrane of Transwell cell capsules (Molecular Devices), at a density of  $2.5 \times 10^5$  cells/well in Ham's F12 medium. The next day, the capsules were transferred in a microphysiometer (Cytosensor, Molecular Devices), and the cells were allowed to equilibrate for approximately two hours by perfusion of 1 mM phosphate-buffered (pH 7.4) RPMI-1640 medium containing 0.2 % BSA. Cells were then exposed to various chemokines diluted in the same medium, for a 2 min duration. Acidification rates were measured at one minute intervals.

Northern blotting

Total RNA was isolated from transfected CHO-K1 cell lines, from a panel of human cell lines of haematopoietic origin and from a panel of dog tissues, using the RNeasy kit (Qiagen). RNA samples (10 µg per lane) were denatured in presence of glyoxal [26], fractionated on a 1 % agarose gel in a 10 mM phosphate buffer (pH 7.0), and transferred to nylon membranes (Pall Biodyne A, Glen Cove, NY) as described [42]. After baking, the blots were prehybridized for 4h at 42° C in a solution consisting of 50 % formamide, 5x Denhardt solution (1x Denhardt: 0.02 % Ficoll, 0.02 % polyvinylpyrrolidone, 0.02 % BSA), 5x SSPE (1x SSPE: 0.18 M NaCl, 10 mM Na phosphate, 1 mM EDTA pH 8.3), 0.3 % Sodium Dodecyl Sulphate (SDS), 250 µg per ml denaturated DNA from herring testes. DNA probes were ( $\alpha^{32}$ P)-labelled by random priming [14]. Hybridizations were carried out for 12h at 42° C in the same solution containing 10 % (wt/vol) dextran sulphate and the heat denaturated probe. Filters were washed up to 0.1x SSC (1x SSC: 150 mM NaCl, 15 mM Na Citrate pH 7.0), 0.1 % SDS at 60° C and autoradiographed at - 70° C using Amersham  $\beta$ -max films.

2. RESULTS AND DISCUSSIONCloning and structural analysis

The sequence homology characterizing genes encoding G protein-coupled receptors has allowed the cloning by low stringency polymerase chain reaction (PCR) of new members of this gene family [24, 34]. One of the clones amplified from mouse genomic DNA, named MOP020 presented strong similarities with characterized chemokine receptors, sharing 80 % identity with the MCP-1 receptor (CCR2) [8], 65 % identity with the MIP-1 $\alpha$ /RANTES receptor (CCR1) [31], and 51 % identity with

IL-8 receptors [20, 30]. The clone was used as a probe to screen a human genomic library. A total of 16 lambda phage clones were isolated. It was inferred from the restriction pattern of each clone and from partial sequence data that all clones were belonging to a single contig (see below) in which two different coding sequences were included. One of the coding sequences was identical to the reported cDNA encoding the CCR2 receptor [8, 44]. A 4.400 pb XbaI fragment of a representative clone containing the second region of hybridization was subcloned in pBluescript SK+. Sequencing revealed a novel gene, tentatively named CCR5, sharing 84 % identity with the MOP020 probe, suggesting that MOP020 is the mouse ortholog of CCR5. MOP020 does not correspond to any of the three mouse chemokine receptor genes cloned recently [16], demonstrating the existence of a fourth murine chemokine receptor.

The sequence of CCR5 revealed a single open reading frame of 352 codons (fig. 1) encoding a protein of 40,600 Da. The sequence surrounding the proposed initiation codon is in agreement with the consensus as described by Kozak [22], since the nucleotide in -3 is a purine. The hydropathy profile of the deduced amino acid sequence is consistent with the existence of 7 transmembrane segments. Alignment of the CCR5 amino acid sequence with that of other functionally characterized human CC-chemokine receptors is represented in figure 2. The highest similarity is found with the CCR2 receptor [8] that shares 75.8 % identical residues. There is also 56.3 % identity with the CCR1 receptor [31], 58.4 % with the CCR3 [10], and 49.1% with the CCR4 [37]. CCR5 represents therefore a new member of the CC-chemokine receptor group [30]. Like the related CCR1 and IL-8 receptors [20, 29, 31, 16] the coding region of CCR5 appears as intronless. From our

partial sequencing data, the CCR2 gene is also devoid of intron in the first two thirds of its coding sequence.

Sequence similarities within the chemokine receptor family are higher in the transmembrane-spanning domains, and  
5 in intracellular loops. As an example, the identity score between CCR5 and CCR2 goes up to 92% when considering the transmembrane segments only. Lower similarities are found in the N-terminal extracellular domain, and in the extracellular loops. The N-terminal domain of the IL-8 and CCR2 receptors  
10 has been shown to be essential for interaction with the ligand [19, 18]. The variability of this region among CC-chemokine receptors presumably contributes to the specificity towards the various ligands of the family.

A single potential site for N-linked glycosylation  
15 was identified in the third extracellular loop of CCR5 (figure 1). No glycosylation site was found in the N-terminal domain of the receptor, where most G protein-coupled receptors are glycosylated. The other chemokine receptors CCR1 and CCR2 present such an N-linked glycosylation site in  
20 their N-terminal domain [31, 8]. By contrast, the CCR3 receptor [10] does not display glycosylation sites neither in the N-terminus, nor in extracellular loops. The active CCR5 receptor has four cysteines in its extracellular segments, and all four are conserved in the other CC- and  
25 CXC-chemokine receptors (figure 2). The cysteines located in the first and second extracellular loops are present in most G protein-coupled receptors, and are believed to form a disulphide bridge stabilizing the receptor structure [41]. The two other cysteines, in the N-terminal segment, and in  
30 the third extracellular loop could similarly form a stabilizing bridge specific to the chemokine receptor family. The intracellular domains of CCR5 do not include potential



sites for phosphorylation by protein kinase C (PKC) or protein kinase A. PKC sites, involved in heterologous desensitization are frequent in the third intracellular loop and C-terminus of G protein-coupled receptors. Such sites, present in CCR3 and CCR2 are represented in figure 1. CCR1 is also devoid of PKC sites. In contrast, all CC-chemokine receptors, are rich in serine and threonine residues in the C-terminal domain. These residues represent potential phosphorylation sites by the family of G protein-coupled receptor kinases, and are probably involved in homologous desensitization [41]. Five of these S/T residues are perfectly aligned in all five receptors (figure 2).

#### Physical linkage of the CCR5 and CCR2 genes

As stated above, the 16 clones isolated with the MOP020 probe corresponded to a single contig containing the CCR5 and CCR2 genes. The organisation of this contig was investigated in order to characterize the physical linkage of the two receptor genes in the human genome. A combination of restriction mapping, Southern blotting, fragment subcloning and partial sequencing allowed to determine the respective borders and overlaps of all clones. Out of the 16 clones, 9 turned out to be characterized by a specific restriction map, and their organization is depicted in figure 3. Four of these clones (#11, 18, 21, 22) contained the CCR2 gene alone, four clones (# 7, 13, 15, 16) contained the ChemR13 gene alone and one clone (#9) contains part of both coding sequences. The CCR2 and CCR5 genes are organized in tandem, CCR5 being located downstream of CCR2. The distance separating CCR2 and CCR5 open reading frames is 17.5 kb. The chromosomal localization of the tandem is presently unknown. Other chemokine receptors have however been located in the

human genome: the CCR1 gene was localized by fluorescence in situ hybridization to the p21 region of human chromosome 3 [16]. The two IL-8 receptor genes, and their pseudogene have been shown to be clustered on the human 2q34-q35 region [1].

- 5 Future studies will demonstrate if CC-chemokine receptor genes do form large clusters in the genome, as do the genes encoding their ligands [4].

10 Functional expression and pharmacology of the active CCR5 receptor

- Stable CHO-K1 cell lines expressing the active CCR5 receptor were established and were screened on the basis of the level of CCR5 transcripts as determined by Northern blotting. Three clones were selected and tested for
- 15 biological responses in a microphysiometer, using various CC- and CXC-chemokines as potential agonists. Wild type CHO-K1 cells were used as control to ensure that the observed responses were specific for the transfected receptor, and did not result from the activation of endogenous receptors. The
- 20 microphysiometer allows the real time detection of receptor activation, by measuring the modifications of cell metabolism resulting from the stimulation of intracellular cascades [33]. Several studies have already demonstrated the potential of microphysiometry in the field of chemokine receptors.
- 25 Modifications of metabolic activity in human monocytes, in response CC-chemokines, were monitored using this system [43]. Similarly, changes in the acidification rate of THP-1 cells (a human monocytic cell line) in response to MCP-1 and MCP-3 have been measured [36]. The estimation of the  $EC_{50}$  for
- 30 both proteins, using this procedure, was in agreement with the values obtained by monitoring the intracellular calcium in other studies [8, 15].

Ligands belonging to the CC- and CXC-chemokine classes were tested on the CCR5 transfected CHO-K1 cells. Whereas MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES were found to be potent activators of the new receptor (figure 4), the CC-chemokines MCP-1, MCP-2 and MCP-3, and the CXC-chemokines GRO $\alpha$  and IL-8 had no effect on the metabolic activity, even at the highest concentrations tested (30 nM). The biological activity of one of the chemokines inducing no response on CCR5 (IL-8) could be demonstrated on a CHO-K1 cell line transfected with the IL-8A interleukin receptor (Mollereau et al., 1993) : IL-8 produced a 160 % increase in metabolic activity as determined using the microphysiometer. The biological activity of the MCP-2 and MCP-3 preparations as provided by J. Van Damme have been widely documented [2, 40]. MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES were tested on the wild type CHO-K1 cells, at a 30 nM-concentration, and none of them induced a metabolic response. On the CCR5 transfected CHO-K1 cell line, all three active ligands (MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES) caused a rapid increase in acidification rate, reaching a maximum by the second or third minute after perfusion of the ligand. The acidification rate returned to basal level within 10 minutes. The timing of the cellular response is similar to that observed for chemokines on their natural receptors in human monocytes [43]. When agonists were applied repeatedly to the same cells, the response was strongly reduced as compared to the first stimulation, suggesting the desensitization of the receptor. All measurements were therefore obtained on the first stimulation of each capsule.

The concentration-effect relation was evaluated for the three active ligands in the 0.3 to 30 nM range (figure 3B and C). The rank order of potency was MIP-1 $\alpha$  > MIP-1 $\beta$  = RANTES. At 30 nM concentrations, the effect of MIP-1 $\alpha$

appeared to saturate (at 156 % of baseline level) while MIP-1 $\beta$  and RANTES were still in the ascending phase. Higher concentrations of chemokines could however not be used. The EC50 was estimated around 3 nM for MIP-1 $\alpha$ . The concentrations  
5 necessary for obtaining a biological response as determined by using the microphysiometer are in the same range as those measured by intracellular calcium mobilization for the CCR1 [31], the CCR2A and B [8], and the CCR3 [10] receptors. The ligand specificity of CCR5 is similar to that reported for  
10 CCR3 [10]. CCR3 was described as the first cloned receptor responding to MIP-1 $\beta$ . However, MIP-1 $\beta$  at 10 nM elicits a significant effect on the CCR5, while the same concentration is without effect on the CCR3 transfected cells [10]. These data suggest that CCR5 could be a physiological receptor for  
15 MIP-1 $\beta$ .

Binding experiments using [ $^{125}$ I]-human MIP-1 $\alpha$  as ligand did not allow to demonstrate specific binding to CCR53 expressing CHO-K1 cells, using as much as 0.4 nM radioligand and 1 million transfected cells per tube. Failure to obtain  
20 binding data could be attributed to a relatively low affinity of the receptor for MIP-1 $\alpha$  and possibly to an inadequate receptor expression level in our CHO cell line.

#### Northern blotting analysis

25 Northern blotting performed on a panel of dog tissues did not allow to detect transcripts for CCR5. Given the role of the chemokine receptor family in mediating chemoattraction and activation of various classes of cells involved in inflammatory and immune responses, the probe was  
30 also used to detect specific transcripts in a panel of human cell lines of haematopoietic origin (figure 5). The panel included lymphoblastic (Raji) and T lymphoblastic (Jurkat)

cell lines, promyeloblastic (KG-1A) and promyelocytic (HL-60) cell lines, a monocytic (THP-1) cell line, an erythroleukemia (HEL 92.1.7) cell line, a megakaryoblastic (MEG-01) cell line, and a myelogenous leukaemia (K-562) cell line. Human  
5 peripheral blood mononuclear cells (PBMC), including mature monocytes and lymphocytes, were also tested. CCR5 transcripts (4.4 kb) could be detected only in the KG-1A promyeloblastic cell line, but were not found in the promyelocytic cell line HL-60, in PBMC, or in any of the other cell lines tested.  
10 These results suggest that the active CCR5 receptor could be expressed in precursors of the granulocytic lineage. CC-chemokines have been reported to stimulate mature granulocytes [27, 38, 23, 2]. However, recent data have also demonstrated a role of CC- and CXC-chemokines in the  
15 regulation of mouse and human myeloid progenitor cell proliferation [6, 7].

CCR5 was shown to respond to MIP-1 $\alpha$ , MIP-1 $\beta$  and RANTES, the three chemokines identified as the major HIV-suppressive factors produced by CD8<sup>+</sup> T cells [9], and  
20 released in higher amounts by CD4<sup>+</sup> T lymphocytes from uninfected but multiply exposed individuals [51]. CCR5 represents a major co-receptor for macrophage-tropic (M-tropic) HIV-1 primary isolates and strains [45, 50]. M-tropic strains predominate during the asymptomatic phase of the  
25 disease in infected individuals, and are considered as responsible for HIV-1 transmission. Strains adapted for growth in transformed T-cell lines (T-tropic strains) use as a co-receptor LESTR (or fusin) [50], an orphan receptor also belonging to the chemokine receptor family, but not yet  
30 characterized functionally [21, 52, 53]. Dual-tropic viruses, which may represent transitional forms of the virus in late stages of infection [54] are shown to use both CCR5 and LESTR

as co-receptors, as well as the CC-chemokine receptors CCR2b and CCR3 [47]. The broad spectrum of co-receptor usage of dual-tropic viruses suggests that within infected individuals, the virus may evolve at least in part from selection by a variety of co-receptors expressed on different cell types.

It is known that some individuals remain uninfected despite repeated exposure to HIV-1 [55, 56, 51]. A proportion of these exposed-uninfected individuals results from the relatively low risk of contamination after a single contact with the virus, but it has been postulated that truly resistant individuals do exist. In fact, CD4<sup>+</sup> lymphocytes isolated from exposed-uninfected individuals are highly resistant to infection by primary M-tropic, but not T-tropic HIV-1 strains. Also, peripheral blood mononuclear cells (PBMC) from different donors are not infected equally with various HIV-1 strains [57-59]. Given the key role played by CCR5 in the fusion event that mediates infection by M-tropic viruses, it is postulated that variants of CCR5 could be responsible for the relative or absolute resistance to HIV-1 infection exhibited by some individuals, and possibly for the variability of disease progression in infected patients [66]. The Inventors selected three HIV-1 infected patients known to be slow progressors, and four seronegative individuals as controls; the full coding region of their CCR5 gene was amplified by PCR and sequenced. Unexpectedly, one of the slow progressors, but also two of the uninfected controls, exhibited heterozygosity at the CCR5 locus for a biallelic polymorphism. The frequent allele corresponded to the published CCR5 sequence, while the minor one displayed a 32 bp deletion within the coding sequence, in a region corresponding to the second extracellular loop of the

receptor (Fig. 6). The figure 6 is the structure of the mutant form of human CC-chemokine receptor 5. a, The amino acid sequence of the non-functional  $\Delta$ ccr5 protein is represented. The transmembrane organization is given by analogy with the predicted transmembrane structure of the wild-type CCR5, although the correct maturation of the mutant protein up to the plasma membrane has not been demonstrated. Amino acids represented in black correspond to unnatural residues resulting from the frame shift caused by the deletion. The mutant protein lacks the last three transmembrane segments of CCR5, as well as the regions involved in G protein-coupling. b, Nucleotide sequence of the CCR5 gene surrounding the deleted region, and translation into the normal receptor (top) or the truncated mutant ( $\Delta$ ccr5, bottom). The 10-bp direct repeat is represented in italics. The nucleotide sequence of the mutant  $\Delta$ ccr5 allele has been deposited with the Genbank/EMBL data libraries under accession number xxxxx. The full size coding region of the CCR5 gene was amplified by PCR, using 5'-TCGAGGATCCAAGATGGATTATCAAGT-3' and 5'-CTGATCTAGAGCCATGTGCACAACTCT-3' as forward and reverse primers respectively. The PCR products were sequenced on both strands using the same oligonucleotides as primers, as well as internal primers, and fluorochrome-labelled dideoxynucleotides as terminators. The sequencing products were run on an Applied Biosystem sequencer, and ambiguous positions were searched along the coding sequence. When the presence of a deletion was suspected from direct sequencing, the PCR products were cloned after restriction with *Bam*HI and *Xba*I endonucleases into pcDNA3. Several clones were sequenced to confirm the deletion. The deletion was identical in three

unrelated individuals investigated by sequencing.

Cloning of the PCR product and sequencing of several clones confirmed the deletion. The deletion causes a frame shift, which is expected to result in premature termination of translation. The protein encoded by this mutant allele ( $\Delta$ CCR5) therefore lacks the last three transmembrane segments of the receptor. A 10-bp direct repeat flanking the deleted region (Fig. 6b) on both sides is expected to have promoted the recombination event leading to the deletion. Numerous mutagenesis studies performed on various classes of G protein-coupled receptors, including chemokine receptors, makes it clear that such a truncated protein is certainly not functional in terms of chemokine-induced signal transduction: it lacks the third intracellular loop and C-terminal cytoplasmic domains, the two regions involved primarily in G protein coupling [41]. In order to test whether the truncated protein was able to function as a HIV-1 co-receptor, the Inventors tested its ability to support membrane fusion by both primary M-tropic and dual-tropic virus env proteins. The recombinant protein was expressed in quail QT6 cells together with human CD4. The QT6 cells were then mixed with HeLa cells expressing the indicated viral env protein and the extent of cell-cell fusion measured using a sensitive and quantitative gene-reporter assay. In contrast to wild-type CCR5, the truncated receptor did not allow fusion with cells expressing the env protein from either M-tropic or dual-tropic viruses (Figure 7). The figure 7 represents the quantification of env protein-mediated fusion by luciferase assay. To quantitate cell-cell fusion events, a modified version of the gene reporter fusion assay described by Nussbaum et al. was used. Japanese quail QT6 fibrosarcoma cells were transfected or



cotransfected as indicated with the pCDNA3 vector (Invitrogen) containing the coding sequence for wild-type CCR5, the truncated  $\Delta$ ccr5 mutant, the CCR2b or the Duffy chemokine receptors, or with the pCDNA3 vector alone. The target cells were also transfected with human CD4 expressed from the CMV promoter and the luciferase gene under the control of the T7 promoter. HeLa effector cells were infected (MOI = 10) with vaccinia vectors expressing T7-polymerase (vTF1.1) and either the JR-FL (vCB28) or 89.6 (vBD3) envelope proteins. The luciferase activity resulting from cell fusion is expressed as the percentage of the activity (in relative light units) obtained for wild-type CCR5. Details concerning plasmid and viral vectors have been previously described. All transfections were performed with an identical quantity of plasmid DNA using pCDNA3 as carrier when necessary. To initiate fusion, target and effector cells were mixed in 24 well plates at 37 °C in the presence of ara-C and rifampicin, and allowed to fuse for 8 hours. Cells were lysed in 150  $\mu$ l of reporter lysis buffer (Promega) and assayed for luciferase activity according to the manufacturer's instructions (Promega).

Coexpression of  $\Delta$ ccr5 with wild-type CCR5 consistently reduced the efficiency of fusion for both JR-FL and 89.6 envelopes, as compared with CCR5 alone. Whether this *in vitro* inhibitory effect (not shared by the chemokine receptor Duffy, used as control) also occurs *in vivo* is presently not known. Coexpression with the CCR2b receptor [31], which is the CC-chemokine receptor most closely related to CCR5 but does not promote fusion by M-tropic HIV-1 strains [48], did not rescue the mutation by formation of a hybrid molecule (Fig. 7).

The figure 8 represents genotyping of individuals

PCR and segregation of the CCR5 alleles in CEPH families. Autoradiography illustrating the pattern resulting from PCR amplification and EcoRI cleavage for individuals homozygous for the wild-type CCR5 allele (CCR5/CCR5), the  $\Delta$ CCR5 allele ( $\Delta$ CCR5/ $\Delta$ CCR5), and for heterozygotes (CCR5/ $\Delta$ CCR5). A 735 bp PCR product is cleaved into a common band of 332 bp for both alleles, and into 403 and 371 bp bands for the wild-type and mutant alleles, respectively. b, Segregation of the CCR5 alleles in two informative families in the CEPH. Half-black and white symbols represent heterozygotes and wild-type homozygotes, respectively. For a few individuals in the pedigrees, DNA was not available (D: not determined). PCRs were performed on genomic DNA samples, using 5'-CCTGGCTGTCGTCCATGCTG-3' and 5'-GATCTAGAGCCATGTGCACAACTCT-3' as forward and reverse primers respectively. Reaction mixtures consisted in 30  $\mu$ l of 10 mM Tris-HCl buffer pH 8.0, containing 50 mM KCl, 0.75 mM MgCl<sub>2</sub>, 2 mM dCTP, dGTP and dTTP, 0.1 mM dATP, 0.5  $\mu$ i [ $\alpha$ -<sup>32</sup>P]-dATP, 0.1% gelatin, 5% DMSO, 200 ng target DNA, 60 ng of each of the primers and 1.5 U Taq polymerase. PCR conditions were: 94 °C for 2 min 30; 93 °C for 1 min, 60 °C for 1 min, 72 °C for 1 min, 30 cycles; 72 °C for 6 min. After the PCR reaction, the samples were incubated for 60 min at 37 °C with 10 U EcoRI, and 2  $\mu$ l of the denatured reaction mixture was applied onto a denaturing 5% polyacrylamide gel containing 8% formamide and 5.6 M urea. Bands were detected by autoradiography.

Based on the 14 chromosomes tested in the first experiment, the deleted  $\Delta$ CCR5 allele appeared rather frequent in the Caucasian population. The accurate frequency was further estimated by testing (Fig. 8a) a large cohort of

Caucasian individuals, including unrelated members of the CEPH (Centre d'Etude des Polymorphismes Humains) families, part of the IRIBHN staff, and a bank of anonymous DNA samples from healthy individuals collected by the Genetics Department of the Erasme Hospital in Brussels. From a total of more than 700 healthy individuals, the allele frequencies were found to be 0.908 for the wild-type allele, and 0.092 for the mutant allele (Table I). The genotype frequencies observed in the population were not significantly different from the expected Hardy-Weinberg distribution (CCR5/CCR5: 0.827 vs 0.824; CCR5/ $\Delta$ CCR5: 0.162 vs 0.167;  $\Delta$ CCR5/ $\Delta$ CCR5: 0.011 vs 0.008,  $p > 0.999$ ), suggesting that the null allele has no drastic effect on fitness. Using two informative CEPH families, it was confirmed that the wild-type CCR5 gene and its  $\Delta$ CCR5 variant were allelic, and segregated in a normal mendelian fashion (Fig. 8b). Interestingly, a cohort of 124 DNA samples originating from Central Africa (collected from Zaire, Burkina Fasso, Cameroun, Senegal and Benin) and Japan did not reveal a single  $\Delta$ CCR5 mutant allele, suggesting that this allele is either absent or very rare in Asian, African black populations (Table I).

The consequences of the existence of a null allele of CCR5 in the normal Caucasian population were then considered in terms of susceptibility to infection by HIV-1. If, as it is predicted, CCR5 plays a major (not redundant) role in the entry of most primary virus strains into cells, then  $\Delta$ CCR5/ $\Delta$ CCR5 individuals should be particularly resistant to HIV-1 challenge, both *in vitro* and *in vivo*. The frequency of the  $\Delta$ CCR5/ $\Delta$ CCR5 genotype should therefore be significantly lower in HIV-1 infected patients, and increased in exposed-uninfected individuals. Also, if heterozygotes have a statistical advantage due to the lower number of functional

receptors on their white blood cells, or to the possible dominant-negative properties of the mutant allele, the frequency of heterozygotes (and mutant alleles) should be decreased in HIV-infected populations. These hypotheses were  
 5 tested by genotyping a large number of seropositive Caucasian individuals ( $n = 645$ ) belonging to cohorts originating from various hospitals from Brussels, Liège and Paris (Table I). Indeed, it was found that within this large series, the frequency of the null  $\Delta\text{CCR5}$  allele was significantly reduced  
 10 from 0.092 to 0.053 ( $p < 10^{-5}$ ). The frequency of heterozygotes was also reduced from 0.162 to 0.106 ( $p < 0.001$ ) and not a single  $\Delta\text{CCR5}/\Delta\text{CCR5}$  individual could be found ( $p < 0.01$ ).

Altogether, functional and statistical data suggest  
 15 that CCR5 is indeed the major co-receptor responsible for natural infection by M-tropic HIV-1 strains. Individuals homozygous for the null  $\Delta\text{CCR5}$  allele (about 1% of the Caucasian population) have apparently a strong resistance to infection. It is unclear at this point whether resistance to  
 20 HIV-1 is absolute or relative, and whether resistance will vary depending on the mode of viral contamination. Larger cohorts of seropositive individuals will have to be tested in order to clarify this point. Heterozygotes have a milder though significant advantage: assuming an equal probability  
 25 of contact with HIV, it can be inferred from Table I that heterozygotes have a 39% reduction in their likeliness of becoming seropositive, as compared to individuals homozygous for the wild-type CCR5 allele. Both a decrease in functional CCR5 receptor number, and a dominant-negative effect of  $\Delta\text{CCR5}$   
 30 *in vivo*, comparable to what is observed in the *in vitro* experiments (Fig. 7) are possible explanations for this relative protection. The mutant allele, which can be regarded

as a natural knock-out in human, is not accompanied by an obvious phenotype in homozygous individuals. Future studies will reveal if subtle correlations can be found with disease states (especially inflammatory, immune or infectious diseases, given the predominant role of chemokine receptors in the recruitment of white blood cells toward the sites of inflammation [4, 61]. Nevertheless, the lack of overt phenotype, taken together with the relative protection that characterizes heterozygous subjects, suggests that pharmacological agents that selectively block the ability of HIV-1 to utilize CCR5 as a cofactor, could be effective in preventing HIV-1 infection, and would be predicted not be associated with major side effects resulting from CCR5 inactivation. These pharmaceutical agents could be used with other compounds which are able to block other chemokine receptors used as co-receptors by some HIV-primary isolates in order to infect other cells [47]. The prevalence of the null allele in the Caucasian population raises the question of whether pandemics of HIV (or related viruses using the same co-receptor) have contributed during mankind's evolution to stabilize by selection the mutant  $\Delta$ ccr5 allele at such a high frequency.

Table 1

	Seronegative			Seropositive			Chi-squared
	Number	Frequency	Standard error	Number	Frequency	Standard error	
Genotypes :							
CCR5/CCR5	582	0.827	0.014	645	0.892	0.012	2 degrees of freedom 17.7 P < 0.0005
CCR5/ $\Delta$ CCR5	114	0.162	0.014	78	0.108	0.012	
$\Delta$ CCR5/ $\Delta$ CCR5	8	0.011	0.004	0	0.000	< 0.001	
Total :	704	1.000		723	1.000		
Alleles :							
CCR5	1278	0.908	0.008	1368	0.946	0.006	1 degree of freedom P < 0.0005
$\Delta$ CCR5	130	0.092	0.008	78	0.054	0.006	
Total :	1408	1.000		1446	1.000		

## REFERENCES

1. Ahuja et al. (1992) *Nature Genetics* 2, 31-36.
2. Alam et al. (1994) *J. Immunol.* 153, 3155-3159.
3. Alam et al. (1992) *J. Exp. Med.* 176, 781-786.
- 5 4. Baggiolini et al. (1994) *Advances in immunology*, Academic press. Ed. Dixon, F.J. 55, 97-179.
5. Birkenbach et al. (1993) *J. Virol.* 67, 2209-2220.
6. Broxmeyer et al. (1990) *Blood* 76, 1110-1116.
7. Broxmeyer et al. (1993) *J. Immunol.* 150, 3448-3458.
- 10 8. Charo et al. (1994) *Proc. Natl. Acad. Sci.* 91, 2752-2756.
9. Cocci et al. (1995) *Science* 270, 1811-1815.
10. Combadiere et al. (1995) *J. Biol. Chem.* 270, 16491-16494.
- 15 11. Desarnaud et al. (1994) *Biochem. J.* 299, 367-373.
12. Devereux et al. (1984) *Nucleic Acids Res.* 12, 387-395.
13. Dobner et al. (1992) *Eur. J. Immunol.* 22, 2795-2799.
14. Feinberg et al. (1983) *Anal. Biochem.* 132, 6-13.
15. Franci et al. (1995) *J. Immunol.* 154, 6511-6517.
- 20 16. Gao et al. (1995) *J. Biol. Chem.* 270, 17494-17501.
17. Gao et al. (1993) *J. Exp. Med.* 177, 1421-1427.
18. Gong et al. (1995) *J. Exp. Med.* 181, 631-640.
19. Hébert et al. (1993) *J. Biol. Chem.* 268, 18549-18533.
20. Holmes et al. (1991) *Science* 253, 1278-1283.
- 25 21. Jazin et al. (1993) *Regul. Peptides* 47, 247-258.
22. Kozak, M. (1989) *J. Cell. Biol.* 108, 229-241.
23. Kuna et al. (1992) *J. Immunol.* 149, 636-642.
24. Libert et al. (1989) *Science* 244, 569-572.
25. Matsuoka et al. (1993) *Biochem. Biophys. Res. Commun.* 194, 504-511.
- 30

26. Mc Master et al. (1977) *Proc. Natl. Acad. Sci. USA* 74, 4835-4838.
27. McColl et al. (1993) *J. Immunol.* 150, 4550-4560.
- 5 28. Mollereau et al. (1993) *Genomics* 16, 248-251.
29. Murphy, P.M. (1994) *Annu. Rev. Immunol.* 12, 593-633.
30. Murphy et al. (1991) *Science* 253, 1280-1283.
31. Neote et al. (1993) *Cell* 72, 415-425.
32. Oppenheim et al. (1991) *Ann. Rev. Immunol.* 9, 617-648.
- 10 33. Owicki et al. (1992) *Biosensors Bioelectronics* 7, 255-272.
34. Parmentier et al. (1989) *Science* 246, 1620-1622.
35. Perret et al. (1990) *Biochem. Biophys. Res. Commun.* 17, 1044-1050.
- 15 36. Pleass et al. (1995) *Fourth International Chemokine Symposium, Bath (UK), 27-30 June, P47.*
37. Power et al. (1995) *J. Biol. Chem.* 270, 19495-19500.
38. Rot et al. (1992) *J. Exp. Med.* 176, 1489-1495.
39. Sambrook et al. (1989) *Molecular Cloning: A Laboratory Manual*, 2nd Ed., Cold Spring Harbor Laboratory, Cold Spring Harbor, NY.
- 20 40. Sozzani et al. (1994) *J. Immunol.* 152, 3615-3622.
41. Strader et al. (1994) *Annu. Rev. Biochem. Ed. Dixon, R.A.F.* 63, 101-132.
- 25 42. Thomas, P. S. (1980). *Proc. Natl. Acad. Sci. USA* 77, 5201-5205.
43. Vaddi et al. (1994) *The FASEB Journal* 8, A502.
44. Yamagami et al. (1994) *Biochem. Biophys. Res. Commun.* 202, 1156-1162.
- 30 45. Deng et al. (1996) *Nature* 381, 661-666.



46. Drajic et al. (1996) *Nature* 381, 667-673.
47. Doranz et al. (1996) *Cell* 85, 1149-1158.
48. Choe et al. (1996) *Cell* 85, 1135-1148.
49. Alkhatib et al. (1996) *Science* 272, 1955-1958.
- 5 50. Feng et al. (1996) *Science* 272, 872-877.
51. Paxton et al. (1996) *Nat. Med.* 2, 412-417.
52. Nomura et al. (1993) *Int. Immunol.* 5, 1239-1249.
53. Loetscher et al. (1994) *J. Biol. Chem.* 269, 232-237.
54. Collman et al. (1992) *J. Virol.* 66, 7517-7521.
- 10 55. Detels et al. (1994) *J. Acquir. Immun. Defic. Sundr.* 7, 1263-1269.
56. Taylor R. J. (1994) *J. NIH Res.* 6, 29-31.
57. Wainberg et al. (1987) *Clin. Exp. Immunol.* 1987, 136-142.
- 15 58. Williams et al. (1991) *Virology* 184, 723-728.
59. Spria et al. (1995) *J. Virol.* 69, 422-429.
60. Haynes et al. (1996) *Science* 271, 324-328.
61. Ben-Baruch et al. (1995) *J. Biol. Chem.* 270, 11703-11706.
- 20 62. Nussbaum et al. (1994) *J. Virol.* 68, 5411-5422.

CLAIMS

1. Peptide having at least an amino sequence which presents more than 80% homology with the amino sequence as represented in SEQ ID NO. 1.

5           2. Peptide according to the claim 1, having at least an amino sequence which presents more than 90% homology with the amino sequence as represented in SEQ ID NO. 1.

          3. Peptide according to the claim 1 or 2, having at least an amino sequence which presents more than 80%  
10 homology with the amino sequence as represented in SEQ ID NO. 2.

          4. Peptide according to the claim 3, having at least an amino sequence which presents more than 90% homology with the amino sequence as represented in SEQ ID NO. 2.

15           5. Peptide according to the claim 2, having at least an amino sequence which presents more than 80% homology with the amino sequence as represented in SEQ ID NO. 3.

          6. Peptide according to the claim 5, having at least an amino sequence which presents more than 90% homology  
20 with the amino sequence as represented in SEQ ID NO. 3.

          7. Peptide according to any of the preceding claims, characterized in that it is a CC chemokine receptor or a portion thereof.

          8. Peptide according to the claim 7, characterized  
25 in that the CC chemokine receptor is stimulated by the MIP-1 $\beta$  chemokine at a concentration  $\leq$  10 nM.

          9. Peptide according to the claim 7 or 8, characterized in that the CC chemokine receptor is stimulated by the MIP-1 $\alpha$  or RANTES chemokines.

30           10. Peptide according to any of the claims 7 to 9, characterized in that the CC chemokine receptor is not

stimulated by the MCP-1, MCP-2, MCP-3, IL-8 and GRO $\alpha$  chemokines.

11. Peptide according to any of the claims 1 to 10,  
characterized in that it is a receptor of HIV-1 and/or HIV-2  
5 viruses or a portion of said HIV viruses.

12. Peptide according to any of the claims 1 to 6,  
characterized in that it is an inactive CC chemokine  
receptor.

13. Peptide according to any of the claims 1 to 6  
10 or 12, characterized in that it is an inactive receptor which  
is not a receptor of HIV-1 and/or HIV-2 viruses or a portion  
of said HIV viruses.

14. Peptide according to any of the claims 7 to 13,  
characterized in that the receptor or the inactive receptor  
15 is a human receptor or a human inactive receptor.

15. Nucleic acid molecule having more than 80%,  
preferably more than 90%, homology with one of the nucleic  
acid sequences shown in figures 1.

16. Nucleic acid molecule according to the claim  
20 15, which has at least the nucleic acid sequence shown in  
figures 1 or a portion (such as a probe or a primer)  
thereof.

17. Nucleic acid molecule encoding the peptide  
according to any of the claims 1 to 14.

25 18. Nucleic acid molecule according to any of the  
claims 15 to 17, wherein the nucleic acid molecule is a DNA  
or a RNA molecule.

19. DNA molecule according to the claim 18, which  
is a cDNA molecule or a genomic DNA molecule.

30 20. Vector comprising the nucleic acid molecule  
according to any of the claims 15 to 19.

21. Vector of the claim 20, adapted for expression in a cell, which comprises the regulatory elements necessary for expression of the nucleic acid molecule in said cell operatively linked to the nucleic acid molecule according to  
5 any of the claims 15 to 19 as to permit expression thereof.

22. Vector of the claim 21, wherein the cell is chosen among the group consisting of bacterial cells, yeast cells, insect cells or mammalian cells.

23. Vector according to any of the claims 20 to 22,  
10 wherein the vector is a plasmid or a virus, preferably a baculovirus, an adenovirus or a semliki forest virus.

24. Vector of the claim 23, wherein the plasmid is the pcDNA3 plasmid.

25. Cell, preferably a human cell, comprising the  
15 vector according to any of the claims 20 to 24.

26. Cell according to the claim 25, characterized in that it is transformed also by another vector encoding a protein enhancing the functional response in said cell, preferably said protein being the Gα15 or the Gα16 protein.

20 27. Cell of the claim 25 or 26, wherein the cell is a mammalian cell, such as a non neuronal cell in origin, which is preferably chosen among the group consisting of CHO-K1, HEK293, BHK21, COS-7 cells.

28. Nucleic acid probe comprising a nucleic acid  
25 molecule of at least 15 nucleotides capable of specifically hybridizing with an unique sequence included within the nucleic acid molecule according to any of the claims 15 to 19.

29. Nucleic acid probe of the claim 28, wherein the  
30 nucleic acid is DNA or RNA.

30. Antisense oligonucleotide having a sequence

capable of specifically hybridizing to a nucleic acid molecule of the claims 15 to 19, so as to prevent translation of said nucleic acid molecule.

31. Antisense oligonucleotide having a sequence  
5 capable of specifically hybridizing to the DNA molecule of the claims 18 or 19 or a portion thereof.

32. Antisense oligonucleotide according to the claim 30 or 31, comprising chemical analogs of nucleotides.

33. Ligand capable of binding to the peptide  
10 according to any of the claims 1 to 14 with the proviso that it is not a known "natural" ligand, preferably chosen among the group consisting of CC-chemokines, HIV viruses or a portion of said HIV viruses.

34. Anti-ligand capable of competitively inhibiting  
15 the binding of the ligand according to the claim 33 to the peptide according to any of the claims 1 to 14.

35. Ligand according to the claim 33, which is an antibody.

36. Anti-ligand according to the claim 34, which  
20 is an antibody.

37. Antibody according to the claim 35 or 36, which is a monoclonal antibody.

38. Monoclonal antibody according to the claim 37, directed to an epitope of the peptide according to any of the  
25 claims 1 to 14, present on the surface of a cell expressing said peptide.

39. Pharmaceutical composition comprising an amount of the oligonucleotide according to claim 30, effective to decrease activity of the peptide according to any of the  
30 claims 1 to 14 by passing through a cell membrane and binding specifically with mRNA encoding said peptide in the cell so

as to prevent its translation, and a pharmaceutically acceptable carrier capable of passing through a cell membrane.

5           40. Pharmaceutical composition of the claim 39, wherein the oligonucleotide is coupled to a substance which inactivates mRNA.

          41. Pharmaceutical composition of the claim 40, wherein the substance which inactivates mRNA is a ribozyme.

10           42. Pharmaceutical composition according to any of the claims 39 to 41, wherein the pharmaceutically acceptable carrier comprises a structure which binds to a receptor on a cell capable of being taken up by cell after binding to the structure.

15           43. Pharmaceutical composition of the claim 42, wherein the structure of the pharmaceutically acceptable carrier is capable of binding to a receptor which is specific for a selected cell type.

          44. Pharmaceutical composition which comprises an  
20 effective amount of the anti-ligand of the claim 34, effective to block binding of a ligand to the peptide according to any of the claims 1 to 14 or an effective amount of the peptide according to any of the claims 1 to 14 or a portion thereof and a pharmaceutically acceptable carrier.

25           45. Transgenic non human mammal expressing the nucleic acid molecule according to any of the claims 15 to 19.

          46. Transgenic non human mammal comprising an homologous recombination knockout of the native peptide  
30 according to any of the claims 1 to 14.

          47. Transgenic non human mammal whose genome

comprises antisense nucleic acid complementary to the nucleic acid molecule according to any of the claims 15 to 19 so placed as to be transcribed into antisense mRNA which is complementary to the nucleic acid molecule of the claims 15  
5 to 19 and which hybridizes to said nucleic acid molecule thereby reducing its translation.

48. Transgenic non human mammal according to any of the claims 45 to 47, wherein the nucleic acid according to any of the claims 15 to 19 additionally comprises an  
10 inducible promoter.

49. Transgenic non human mammal according to any of the claims 45 to 48, wherein the nucleic acid according to claim 15 to 19 additionally comprises tissue specific regulatory elements.

15 50. Transgenic non human mammal according to any of the claims 45 to 49, which is a mouse.

51. Method for determining whether a ligand can specifically bind to a peptide according to any of the claims 1 to 14, which comprises contacting a cell transfected with  
20 a vector expressing the nucleic acid molecule encoding said peptide with the ligand under conditions permitting binding of ligand to such peptide and detecting the presence of any such ligand bound specifically to said peptide, thereby determining whether the ligand binds specifically to said  
25 peptide.

52. Method for determining whether a ligand can specifically bind to the peptide according to any of the claims 1 to 14, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid  
30 molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the ligand with the

membrane fraction under conditions permitting binding of the ligand to such peptide and detecting the presence of any ligand bound to said peptide, thereby determining whether the compound is capable of specifically binding to said peptide.

5           53. Method for determining whether a ligand is an agonist of the peptide according to any of the claims 1 to 14, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide with the ligand under conditions permitting the  
10 activation of a functional receptor response from the cell and detecting by means of a bio-assay, such as a second messenger response, an increase in the peptide activity, thereby determining whether the ligand is a peptide agonist.

          54. Method for determining whether a ligand is an  
15 agonist of the peptide according to any of the claims 1 to 14, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the membrane fraction with  
20 the ligand under conditions permitting the activation of a functional peptide response and detecting by means of a bio-assay, such as a second messenger response, an increase in the peptide activity, thereby determining whether the ligand is a peptide agonist.

25           55. Method for determining whether a ligand is an antagonist of the peptide according to any of the claims 1 to 14, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide with the ligand in the presence of a known peptide  
30 agonist, under conditions permitting the activation of a functional peptide response and detecting by means of a bio-



assay, such as a second messenger response, a decrease in the peptide activity, thereby determining whether the ligand is a peptide antagonist.

56. Method for determining whether a ligand is an  
5 antagonist of the peptide according to any of the claims 1 to 14, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the membrane fraction with  
10 the ligand in the presence of a known peptide agonist, under conditions permitting the activation of a functional peptide response and detecting by means of a bio-assay, such as a second messenger response, a decrease in the peptide activity, thereby determining whether the ligand is a  
15 receptor antagonist.

57. A method according to any of the claims 51 to 56, wherein the second messenger assay comprises measurement of calcium ions ( $\text{Ca}^{2+}$ ), inositol phosphates (such as  $\text{IP}_3$ ), diacylglycerol (DAG) or cAMP.

20 58. Method according to any of the claims 51 to 57, wherein the cell is a mammalian cell, preferably non neuronal in origin, and chosen among the group consisting of CHO-K1, HEK293, BHK21 and COS-7 cells.

59. Method according to any of the claims 51 to 58,  
25 wherein the ligand is not previously known.

60. Ligand detected by the method according to any of the claims 51 to 59.

61. Pharmaceutical composition which comprises the ligand according to the claim 60 and a pharmaceutically  
30 acceptable carrier.

62. Method of screening drugs to identify drugs

which specifically bind to the peptide according to any of the claims 1 to 14 on the surface of the cell, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide  
5 with a plurality of drugs under conditions permitting binding of said drugs to the peptide, and determining those drugs which specifically bind to the transfected cell, thereby identifying drugs which specifically bind to the peptide.

63. Method of screening drugs to identify drugs  
10 which specifically bind to the peptide according to any of the claims 1 to 14 on the surface of the cell, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cell  
15 extract, contacting the membrane fraction with a plurality of drugs and determining those drugs which bind to the transfected cell, thereby identifying drugs which specifically bind to said peptide.

64. Method of screening drugs to identify drugs  
20 which act as agonists of the peptide according to any of the claims 1 to 13, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide with a plurality of drugs under conditions permitting the activation of a functional peptide response,  
25 and determining those drugs which activates such peptide using a bio-assay, such as a second messenger response, thereby identifying drugs which act as peptide agonists.

65. Method of screening drugs to identify drugs  
which act as agonists of the peptide according to any of the  
30 claims 1 to 14, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid

molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the membrane fraction with a plurality of drugs under conditions permitting the activation of a functional peptide response, and determining  
5 those drugs which activate such peptide using a bio-assay, such as a second messenger response, thereby identifying drugs which act as peptide agonists.

66. Method of screening drugs to identify drugs which act as antagonists of the peptide according to any of  
10 the claims 1 to 14, which comprises contacting a cell transfected with a vector expressing the nucleic acid molecule encoding said peptide with a plurality of drugs in the presence of a known peptide agonist, under conditions permitting the activation of a functional peptide response,  
15 and determining those drugs which inhibit the activation of the peptide using a bio-assay, such as a second messenger response, thereby identifying drugs which act as peptide antagonists.

67. Method of screening drugs to identify drugs  
20 which act as antagonists of the peptide according to any of the claims 1 to 14, which comprises preparing a cell extract from cells transfected with a vector expressing the nucleic acid molecule encoding said peptide, isolating a membrane fraction from the cell extract, contacting the membrane  
25 fraction with a plurality of drugs in presence of a known peptide agonist, under conditions permitting the activation of a functional peptide response, and determining those drugs which inhibit the activation of the peptide using a bio-assay, such as a second messenger response, thereby  
30 identifying drugs which act as peptide antagonists.

68. Method according to any of the claims 64 to 67,

wherein the functional response detected by means of a bioassay is detected and measured by a microphysiometer.

69. Drug detected by any of the methods according to claims 62 to 68.

5           70. Pharmaceutical composition comprising a drug according to the claim 69 and a pharmaceutically acceptable carrier.

71. Method of detecting the expression of the peptide according to any of the claims 1 to 14, by detecting  
10 the presence of mRNA coding said receptor, which comprises obtaining total mRNA from the cell and contacting the mRNA so obtained with the nucleic acid probe according to the claim 28 under hybridizing conditions, and detecting the presence of mRNA hybridized to the probe, thereby detecting  
15 the expression of the peptide by the cell.

72. Method of detecting the presence of the peptide according to any of the claims 1 to 13 on the surface of a cell, which comprises contacting the cell with the anti-ligand of claim 34 under conditions permitting binding of the  
20 antibody to the peptide, and detecting the presence of the antibody bound to the cell, thereby detecting the presence of the peptide on the surface of the cell.

73. Method of determining the physiological effects of expressing varying levels of the peptide according to any  
25 of the claims 1 to 14, which comprises producing a transgenic non human mammal according to any of the claims 45 to 50 whose levels of peptide expression are varied by use of an inducible promoter which regulates the peptide regulation.

74. Method of determining the physiological effects  
30 of expressing varying levels of the peptide according to any of the claims 1 to 14, which comprises producing a panel of

transgenic non human mammals according to any of the claims 45 to 50, each expressing a different amount of said peptide.

75. Method for identifying an antagonist of the peptide according to any of the claims 1 to 13 capable of  
5 alleviating an abnormality in a subject wherein the abnormality is alleviated by decreasing the activity of the peptide, which comprises administering the antagonist to a transgenic non human mammal according to any of the claims 45 to 50 and determining whether the antagonist alleviates  
10 the physical and behavioural abnormalities displayed by the transgenic non human mammal as a result of peptide activity, thereby identifying the antagonist.

76. Antagonist identified by any of the methods of the claims 71 to 75.

15 77. Pharmaceutical composition comprising an antagonist according to the claim 76 and a pharmaceutically acceptable carrier.

78. Method for identifying an agonist of the peptide according to any of the claims 1 to 13 capable of  
20 alleviating an abnormality in a subject wherein the abnormality is alleviated by activation of said peptide, which comprises administering the agonist to a transgenic non human mammal according to any of the claims 45 to 50 and determining whether the antagonist alleviates the physical  
25 and behavioural abnormalities displayed by the transgenic non human mammal, the alleviation of the abnormalities indicating the identification of the agonist.

79. Agonist identified by the method of the claim 78.

30 80. Pharmaceutical composition comprising an agonist according to the claim 79 and a pharmaceutically

acceptable carrier.

81. Method for diagnosing a predisposition or a resistance to a disorder associated with the activity of a specific allele of the peptide according to any of the claims 1 to 14, and/or associated with infectious agents present in a subject, which comprises :

- a) obtaining nucleic acid molecules of a subject;
- b) possibly performing a restriction digest of said nucleic acid molecules with a panel of restriction enzymes;
- 10 c) possibly electrophoretically separating the resulting nucleic acid fragments on a sized gel;
- d) contacting the resulting gel or the obtained nucleic acid molecules labelled with a nucleic acid probe with a detectable marker and capable of specifically hybridizing to said nucleic acid molecule;
- 15 e) detecting labelled bands or in situ nucleic acid molecules which have hybridized to the said nucleic acid molecule labelled with a detectable marker to create a unique band pattern or in situ marking specific to the subject;
- 20 f) preparing other nucleic acid molecules obtained from other patients for diagnosis by step a-e; and
- g) comparing the unique band pattern specific to the nucleic acid molecule of subjects suffering from the disorder from step e and the nucleic acid molecule obtained for diagnosis from step f to determine whether the patterns are the same or different and to diagnose thereby predisposition or resistance to the disorder if the patterns are the same or different.
- 25

30 82. Method for diagnosing a predisposition or a resistance to a disorder associated with the activity of a specific allele of the peptide according to any of the claims

1 to 14 or the presence of said peptide at the surface of cells, and/or associated with infectious agents present in a subject, which comprises :

- a) obtaining a sample of a body fluid, preferably a blood sample comprising antigen presenting cells, from a subject,
- b) adding to said sample a ligand and/or an anti-ligand according to any of the claims 33 to 38,
- c) detecting the cross-reaction between said ligand and/or said anti-ligand and the specific peptide, and
- d) determining whether the peptide corresponds to a receptor or an inactive receptor according to the claim 7 and diagnosing thereby a predisposition or a resistance to the disorder according to the type of the peptide present in the body fluid of the subject.

83. Diagnostic and/or dosage device comprising the peptide according to any of the claims 1 to 14, the nucleic acid molecule according to any of the claims 15 to 19, the nucleic acid probe according to any of the claims 28 to 29, the ligand and anti-ligand according to any of the claims 33 to 38, being possibly labelled with a detectable marker, their portions (such as primer, probes, epitopes, ...) or a mixture thereof.

84. Diagnostic device according to the claim 83, characterized in that it comprises the reactants for the detection and/or dosage of antigens, antibodies or nucleic acid sequences through a method selected from the group consisting of in situ hybridization, hybridization or recognition by marked specific antibodies, specially ELISA ® (Enzyme Linked Immunosorbent Assay) or RIA ® (Radio Immunoassay), methods on filter, on a solid support, in

solution, in "sandwich", on gel, by Dot blot hybridization, by Northern blot hybridization, by Southern blot hybridization, by isotopic or non-isotopic labelling (such as immunofluorescence or biotinylation), by a technique of cold probes, by genetic amplification, particularly PCR, LCR or CPR, by a double immunodiffusion, by a counter-immunoelectrophoresis, by haemagglutination and/or a mixture thereof.

85. Method of preparing the purified peptide according to any of the claims 1 to 14, which comprises :
- a) constructing a vector adapted for expression in a cell which comprises the regulatory elements necessary for the expression of nucleic acid molecules in the cell operatively linked to nucleic acid molecule encoding said peptide so as to permit expression thereof, wherein the cell is selected from the group consisting of bacterial cells, yeast cells, insect cells and mammalian cells;
  - b) inserting the vector of step a in a suitable host cell;
  - c) incubating the cell of step b under conditions allowing the expression of the peptide according to the invention;
  - d) recovering the peptide so obtained; and
  - e) purifying the peptide so recovered, thereby preparing an isolated peptide according to the invention.

86. Use of the pharmaceutical composition according to any of the claims 39 to 44, 61, 70, 77 and 80, for the preparation of a medicament in the treatment of a disease chosen from the group consisting of inflammatory diseases, including rheumatoid arthritis, glomerulonephritis, asthma, idiopathic pulmonary fibrosis and psoriasis, viral infections including infections by Human Immunodeficiency Viruses 1 and 2 (HIV-1 and 2), cancer including leukaemia, atherosclerosis and/or auto-immune disorders.



**ABSTRACT****ACTIVE AND INACTIVE CC-CHEMOKINES RECEPTOR AND NUCLEIC  
ACID MOLECULES ENCODING SAID RECEPTOR.**

5

The present invention is related to new peptides and the nucleic acid molecules encoding said peptides.

The present invention concerns also the vector comprising said nucleic acid molecules, cells transformed by  
10 said vector, inhibitors directed against said peptides or said nucleic acid molecules, a pharmaceutical composition and a diagnostic and/or dosage device comprising said products, and non human transgenic animals expressing the peptides according to the invention or the nucleic acid molecules  
15 encoding said peptides.

(Figure 6)

SEQ ID NO.1FIG.1 a

GAATTCCCCAACAGAGCCAAGCTCTCCATCTAGTGGACAGGGAAGCTAGCAGCAAACC 59  
I P P T E P S S P S S G Q G S \* Q Q T 19

TTCCCTTCACTACAAAACCTTCATTGCTTGGCCAAAAAGAGAGTTAATTCAATGTAGACAT 119  
F P S L Q N F I A W P K R E L I Q C R H 39

CTATGTAGGCAATTAAAAACCTATTGATGTATAAAACAGTTTGCATTTCATGGAGGGCAAC 179  
L C R Q L K T Y \* C I K Q F A F M E G N 59

TAAATACATTCTAGGACTTTATAAAAGATCACTTTTTTATTATGCACAGGGTGAACAAG 239  
\* I H S R T L \* K I T F Y L C T G W N R 79

ATGGATTATCAAGTGTCAAGTCCAATCTATGACATCAATTATTATACATCGGAGCCCTGC 299  
M D Y Q V S S P I Y D I N Y Y T S E P C 99

CAAAAAATCAATGTGAAGCAAATCGCAGCCCGCCTCCTGCCTCCGCTCTACTCACTGGTG 359  
Q K I N V K Q I A A R L L P P L Y S L V 119

TTCATCTTTGGTTTTGTGGGCAACATGCTGGTCATCCTCATCCTGATAAACTGCAAAAGG 419  
F I F G F V G N M L V I L I L I N C K R 139

CTGAAGAGCATGACTGACATCTACCTGCTCAACCTGGCCATCTCTGACCTGTTTTTCCTT 479  
L K S M T D I Y L L N L A I S D L F F L 159

CTTACTGTCCCCTTCTGGGCTCACTATGCTGCCGCCAGTGGGACTTTGGAAATACAATG 539  
L T V P F W A H Y A A A Q W D F G N T M 179

TGTCAACTCTTGACAGGGCTCTATTTTATAGGCTTCTTCTCTGGAATCTTCTTCATCATC 599  
C Q L L T G L Y F I G F F S G I F F I I 199

CTCCTGACAATCGATAGGTACCTGGCTGTCTGTCATGCTGTGTTTGCTTTAAAGCCAGG 659  
L L T I D R Y L A V V H A V F A L K A R 219

ACGGTCACCTTTGGGGTGGTGACAAGTGTGATCACTTGGGTGGTGGCTGTGTTTGCGTCT 719  
T V T F G V V T S V I T W V V A V F A S 239

CTCCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTCT 779  
L P G I I F T R S Q K E G L H Y T C S S 259

CATTTTCCATACA  
H F P Y

GAATTC	CCCCCAACAGAGCCAAGCTCTCCATCTAGTGGACAGGGAAGCTAGCAGCAAACC	59
I P P T E P S S P S S G Q G S *	Q Q T	19
TTCCCTTCACTACAAA	CTTCATTGCTTGGCCAAAAAGAGAGTTAATTCAATGTAGACAT	119
F P S L Q N F I A W P K R E L I Q C R H		39
CTATGTAGGCAATTAAAA	CCTATTGATGTATAAAACAGTTTGCATTATGGAGGGCAAC	179
L C R Q L K T Y * C I K Q F A F M E G N		59
TAAATACATTCTAGGACTTTATAAAAGATCACTTTTTATTTATGCACAGGGTGGAAACAAG		239
* I H S R T L * K I T F Y L C T G W N K		79
ATGGATTATCAAGTGTCAAGTCCAATCTATGACATCAATTATTATACATCGGAGCCCTGC		299
M D Y Q V S S P I Y D I N Y Y T S E P C		99
CAAAAAATCAATGTGAAGCAAATCGCAGCCCGCCTCCTGCCTCCGCTCTACTCACTGGTG		359
Q K I N V K Q I A A R L L P P L Y S L V		119
TTTCATCTTTGGTTTTGTGGGCAACATGCTGGTCACTCCTCATCCTGATAAACTGCAAAAGG		419
F I F G F V G N M L V I L I L I N C K R		139
CTGAAGAGCATGACTGACATCTACCTGCTCAACCTGGCCATCTCTGACCTGTTTTTCCTT		479
L K S M T D I Y L L N L A I S D L F F L		159
CTTACTGTCCCCTTCTGGGCTCACTATGCTGCCGCCAGTGGGACTTTGGAAATACAATG		539
L T V P F W A H Y A A A Q W D F G N T M		179
TGTCAACTCTTGACAGGGCTCTATTTTATAGGCTTCTTCTCTGGAATCTTCTTCATCATC		599
C Q L L T G L Y F I G F F S G I F F I I		199
CTCCTGACAATCGATAGGTACCTGGCTGTGCTCCATGCTGTGTTTGCTTTAAAAGCCAGG		659
L L T I D R Y L A V V H A V F A L K A R		219
ACGGTCACCTTTGGGGTGGTGACAAGTGTGATCACTTGGGTGGTGGCTGTGTTTGCGTCT		719
T V T F G V V T S V I T W V V A V F A S		239
CTCCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTCT		779
L P G I I F T R S Q K E G L H Y T C S S		259
CATTTTCCATACATTAAAGATAGTCATCTTGGGGCTGGTCCTGCCGCTGCTTGTGATGGT		839
H F P Y I K D S H L G A G P A A A C H G		279

CATCTGCTACTCGGGAATCCTAAAACTCTGCTTCGGTGTGCGAAATGAGAAGAAGAGGCA	899
H L L L G N P K N S A S V S K * E E E A	299
CAGGGCTGTGAGGCTTATCTTCACCATCATGATTGTTTATTTCTCTTCTGGGCTCCCTA	959
Q G C E A Y L H H H D C L F S L L G S L	319
CAACATTGTCTTCTCCTGAACACCTTCCAGGAATTCTTTGGCCTGAATAATTGCAGTAG	1019
Q H C P S P E H L P G I L W P E * L Q *	339
CTCTAACAGGTTGGACCAAGCTATGCAGGTGACAGAGACTCTTGGGATGACGCACTGCTG	1079
L * Q V G P S Y A G D R D S W D D A L L	359
CATCAACCCCATCATCTATGCCTTTGTGCGGGGAGAAGTTCAGAACTACCTCTTAGTCTT	1139
H Q P H H L C L C R G E V Q K L P L S L	379
CTTCCAAAAGCACATTGCCAAACGCTTCTGCAAATGCTGTTCTATTTTCCAGCAAGAGGC	1199
L P K A H C Q T L L Q M L F Y F P A R G	399
TCCCGAGCGAGCAAGCTCAGTTTACACCCGATCCACTGGGGAGCAGGAAATATCTGTGGG	1259
S R A S K L S L H P I H W G A G N I C G	419
CTTGTGACACGGACTCAAGTGGGCTGGTGACCCAGTCAGAGTTGTGCACATGGCTTAGTT	1319
L V T R T Q V G W * P S Q S C A H G L V	439
TTCATACACAGCCTGGGCTGGGGGTNGGTTGGNNGAGGTCTTTTTTAAAGGAAGTTACT	1379
F I H S L G W G X V G X G L F * K E V T	459
GTTATAGAGGGTCTAAGATTATCCATTATTTGGCATCTGTTTAAAGTAGATTAGATCC	1439
V I E G L R F I H L F G I C L K * I R S	479
GAATTC	
E F	

SEQ ID NO.2 (SUITE)

FIG.1 c

## SEQ ID NO.3


## FIG.1 d

GAATTCCCCAACAGAGCCAAGCTCTCCATCTAGTGGACAGGGAAGCTAGCAGCAAACC	59
I P P T E P S S P S S G Q G S * Q Q T	19
TTCCCTTCACTACAAAACCTTCATTGCTTGGCCAAAAGAGAGTTAATTCAATGTAGACAT	119
F P S L Q N F I A W P K R E L I Q C R H	39
CTATGTAGGCAATTAAAAACCTATTGATGTATAAACAGTTTGCATTTCATGGAGGGCAAC	179
L C R Q L K T Y * C I K Q F A F M E G N	59
TAAATACATTCTAGGACTTTATAAAAGATCACTTTTTATTATGCACAGGGTGAACAAG	239
* I H S R T L * K I T F Y L C T G W N K	79
ATGGATTATCAAGTGTCAAGTCCAATCTATGACATCAATTATTATACATCGGAGCCCTGC	299
M D Y Q V S S P I Y D I N Y Y T S E P C	99
CAAAAAATCAATGTGAAGCAAATCGCAGCCCGCCTCCTGCCTCCGCTCTACTCACTGGTG	359
Q K I N V K Q I A A R L L P P L Y S L V	119
TTCACTTTTGGTTTTGTGGGCAACATGCTGGTCATCCTCATCCTGATAAACTGCAAAGG	419
F I F G F V G N M L V I L I L I N C K R	139
CTGAAGAGCATGACTGACATCTACCTGCTCAACCTGGCCATCTCTGACCTGTTTTCTT	479
L K S M T D I Y L L N L A I S D L F F L	159
CTTACTGTCCCCTTCTGGGCTCACTATGCTGCCGCCAGTGGGACTTTGGAAATACAATG	539
L T V P F W A H Y A A A Q W D F G N T M	179
TGTCAACTCTTGACAGGGCTCTATTTTATAGGCTTCTTCTCTGGAATCTTCTTCATCATC	599
C Q L L T G L Y F I G F F S G I F F I I	199
CTCCTGACAATCGATAGGTACCTGGCTGTCTCGTCCATGCTGTGTTTGCTTTAAAAGCCAGG	659
L L T I D R Y L A V V H A V F A L K A R	219
ACGGTCACCTTTGGGGTGGTGACAAGTGTGATCACTTGGGTGGTGGCTGTGTTTGCCTCT	719
T V T F G V V T S V I T W V V A V F A S	239
CTCCAGGAATCATCTTTACCAGATCTCAAAAAGAAGGTCTTCATTACACCTGCAGCTCT	779
L P G I I F T R S Q K E G L H Y T C S S	259
CATTTTCCATACAGTCAGTATCAATTCTGGAAGAATTTCCAGACATTAAAGATAGTCATC	839
H F P Y S Q Y Q F W K N F Q T L K I V I	279

TTGGGGCTGGTCCTGCGCTGCTTGTGTCATGGTCATCTGCTACTCGGGAATCCTAAAACT	899
L G L V L P L L V M V I C Y S G I L K T	299
CTGCTTCGGTGTGCGAAATGAGAAGAAGAGGCACAGGGCTGTGAGGCTTATCTTCACCATC	959
L L R C R N E K K R H R A V R L I F T I	319
ATGATTGTTTATTTTCTTCTGCGGCTCCCTACAACATTGTCCTTCTCCTGAACACCTTC	1019
M I V Y F L F W A P Y N I V L L L N T F	339
CAGGAATTCTTTGGCCTGAATAATTGCAGTAGCTCTAACAGGTTGGACCAAGCTATGCAG	1079
Q E F F G L N N C S S S N R L D Q A M Q	359
GTGACAGAGACTCTTGGGATGACGCACTGCTGCATCAACCCCATCATCTATGCCTTTGTC	1139
V T E T L G M T H C C I N P I I Y A F V	379
GGGAGAAGTTCAGAACTACCTCTTAGTCTTCTTCCAAAAGCACATTGCCAAACGCTTC	1199
G E K F R N Y L L V F F Q K H I A K R F	399
TGCAAATGCTGTTCTATTTTCCAGCAAGAGGCTCCCGAGCGAGCAAGCTCAGTTTACACC	1259
C K C C S I F Q Q E A P E R A S S V Y T	419
CGATCCACTGGGGAGCAGGAAATATCTGTGGGCTTGTGACACGGACTCAAGTGGGCTGGT	1319
R S T G E Q E I S V G L * H G L K W A G	439
GACCCAGTCAGAGTTGTGCACATGGCTTAGTTTTATACACAGCCTGGGCTGGGGGTNGG	1379
D P V R V V H M A * F S Y T A W A G G X	459
TTGGNNGAGGTCTTTTTTAAAAGGAAGTTACTGTTATAGAGGGTCTAAGATTCATCCATT	1439
L X E V F F K R K L L L * R V * D S S I	479
TATTTGGCATCTGTTTAAAGTAGATTAGATCCGAATTC	
Y L A S V * S R L D P N	

FIG. 2

CCR5	1 M Y Q V S S P I P D I N Y T S E P C Q R I N V K Q I W A N I L P P L Y S I V E I F G F V G N M I V I I L I N C K R L K S M T D I Y L L N L A I S D I E F L I T I	83
hcc-R2b	M L S T S R S R I R N I N E S G E E V T T E F T D Y G A L C I K E T N K Q I W A I I P P L Y S I V E I F G F V G N M I V I I L I N C K R L K S M T D I Y L L N L A I S D I E F L I T I	95
hcc-R3	M T T S I I J V E T F G T S Y I D D V G L I J E V A D T R A I A N E F V P P L Y S L V F I P W I I I G N V A V M I L J K Y B R I R I N I Y L L N L A I S D I E F I M I	87
hcc-R1	M E T P N T T E D Y D T T E F T G D A T P C Q R I N V K Q I W A N I L P P L Y S I V E I F G F V G N M I V I I L I N C K R L K S M T D I Y L L N L A I S D I E F L I T I	87
hcc-R4	M N P T D I A D T T L D E S I Y S N I Y L E S I P K P C I K E G I K A F G E L I L P P L Y S L V E N E G I I G N S V W I J F K Y K R I R S M T D I Y L L N L A I S D I E F V F S	92
CCR5	V P F W A I I Y A I A N O M F G N I M C Q I L T G L Y I G F F S G I F F I I L L T I D R Y L A V I I A V F A I K A R T V T E G V T S V I T W W A V F A S L P G I I F T R S Q K E G I I	177
hcc-R2b	I P I W A I I S A I A N E M V F G N I M C Q I E T G I Y I G F F I I I L T I D R Y L A V I I A V F A I K A R T V T E G V T S V I T W I A V F A S V P G I I F T K C K E D S V	189
hcc-R3	I P F W I I Y V R G I N M V F C I K M C N L I E C P M I T A Y E F I F F I I L T I D R Y L A V I I A V F A I K A R T V T E G V I T V C N G I A V I I F I I Y E T E E L F E E	182
hcc-R1	I P F W I I L Y K L K D I M V F C I K M C N L I E S G F Y I T C L Y S E I F F I I L L T I D R Y L A V I I A V F A I K A R T V T E G V I T S I I M A I I A S M P G I Y E S K T I M E F I I	182
hcc-R4	L P F W G Y Y A I A I O M V E G L I G I K M I S M Y L V G E N S G I F F I I M S I D R Y L A V I I A V F A I K A R T V T E G V I T S I I M A I I A S M P G I Y E S T C Y I E R N I	186
CCR5	Y T C S I I F P Y S Q Q F M K N F Q T L K I V I L G L V L P I I V M V I C Y S G I I K T I L R C N E K K R I R A V R L I F T I M I V Y F L F W A P Y N I V L L I N T F Q E F F G L N N C	272
hcc-R2b	V M I C Y E T I G . . . M Q E F I I M R N I I G L V I P I I I V I C Y S G I I K T I L R C N E K K R I R A V R L I F T I M I V Y F L F W I P Y N I V I I I N T F Q E F F G I I N C	280
hcc-R3	T I I S A L Y I E I Y V Y S M I I I P I I M T I I F C I V I P L I V M I C Y I I I K I T I L R C I P I I K Y Q I I I I I V I N A V I I I J S I I I F C I I	276
hcc-R1	I F C S I I F P I E S L R E W K I E Q A L K N L F G L V L P L V I I C Y I I G I I I I L L R R P E K K S K A V R L I F V I M I I F F L F W I P Y N I T I I T S V F Q I E F T H E C	276
hcc-R4	T Y O K T Y S I N S T I W K V L S S I F N I I L G L V I P I I G I I I F C Y S M I I R T I I D H C N E K K N K A V K M I F A V V V L F L G E M P Y N I V I I F E F I V E L E V I Q D C	279
CCR5	S G S I I I I D Q M Q V T E T L G M T H C C I N P I I Y A F V G E K E R I Y L I V F F C I I I A K R I E C K I S I F C I A V E R N S S V Y I I S T G E Q E I S M G I	352
hcc-R2b	F S I F S Q I D Q M I V T E T L G M T H C C I N P I I Y A F V G E K E R I Y I S V F E R K I I I E C K I C P V E Y U I I V D G V T I I N I S T G E Q E I S M G I	360
hcc-R3	F I R K I I I I V I I V T E T A V S I C C I N I I Y A F V G I I F F N Y I I R U E T I I I I I M I I I G R Y I P E I I E R I S S V I S I S I I F I E I I S I V T	355
hcc-R1	E C S I I I I I I D I M Q V T E T A V I C C I N I I Y A F V G I I F F N Y I R Q I E H R R V V I I I M L P E I S V D R I E N S S I I S I S I G I E I I S A K I	355
hcc-R4	T T E R Y I D Y A I A I A T E T I A F V I C C I N P I I I F E I G E K E R I I I Q I E K I G L E V I G O Y G L I I Y S A D T F S S Y T C S I M D I D L I D R I	360

FIG. 3






FIG. 4a




FIG. 4b

9/12






FIG. 5



**FIG. 6**



A.




FIG. 7a

B.




FIG. 7b

12/12




FIG. 8

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**